Clinical Trials Logo

Clinical Trial Summary

The goal of this research is to validate novel non-invasive Magnetic resonance imaging (MRI) biomarkers to detect Gastroesophageal varices (GEV) in patients with cirrhosis, including fractional flow change in the portal vein and elevated azygos flow. End-stage liver disease (cirrhosis) is characterized by advanced fibrosis, liver failure, and portal hypertension. There are many causes of cirrhosis, including viral hepatitis, alcohol abuse, and perhaps most importantly, non-alcoholic fatty liver disease (NAFLD) and its aggressive subset, non-alcoholic steatohepatitis (NASH). 3 million new cases of end-stage liver disease (cirrhosis) are expected over the next decade. In cirrhosis, portosystemic collaterals that shunt blood away from the liver develop due to increased portal pressure. Gastroesophageal varices (GEV) are the most clinically relevant because they can cause fatal internal bleeding. GEV bleeding carries ~20% mortality at 6 weeks, and ~34% overall mortality. Identification of at-risk varices, prior to bleeding, is of paramount importance to initiate primary prophylaxis. To identify and treat at-risk patients, current guidelines recommend regular esophagogastroduodenoscopy (EGD) and variceal band ligation. Detection of high-risk GEV is key to initiating primary prophylaxis, which can reduce mortality by 50-70%. However, endoscopy is invasive and often unnecessary when no treatment is required. Therefore, the American Association for the Study of Liver Diseases has identified the development of "non-invasive markers that predict the presence of high-risk varices" as a major unmet need.


Clinical Trial Description

The overall goal of this research is to implement advanced non-invasive 4D flow MRI biomarkers to predict the presence of treatable but potentially lethal GEV in patients with cirrhosis. This would facilitate the triage of patients with high-risk GEV to therapeutic EGD, while reducing unnecessary EGD procedures in patients without them. The primary biological mechanism for development of GEV is elevated portal pressure and reversal of flow in the left gastric vein (LGV). Applying 4D flow MRI, investigators aim to detect and quantify reversed flow in the LGV to detect GEV at risk for bleeding. Aim 1: Perform pre-clinical validation of an optimized, accelerated radial 4D flow MRI strategy. Aim 2: Determine the diagnostic performance of radial 4D flow MRI, in cirrhotic adults including 1. diagnostic accuracy to identify high-risk GEV using EGD as reference standard, and 2. test-retest repeatability Aim 3: Evaluate the effects and added value of a meal challenge to assess for high-risk GEV. Aim 4: Compare the accuracy of 4D flow MRI to current non-invasive markers of liver disease. Research Procedures Pre-Clinical Validation (Phase 1): A total of 21 participants (7 healthy volunteers, 7 patients with small, low-risk, and 7 with large, high-risk GEV) will be enrolled. Participants will be asked to complete a single research visit that will include a contrast enhanced MRI scan lasting up to 1 hour. Participants will be screening a final time for contraindications to contrast enhanced MR imaging; an IV will be placed; and participants will be positioned in the MR scanner, asked to lie as still as possible and to follow some breath hold instructions. Clinical Validation (Phase 2-3): A total of 100 patients diagnosed with cirrhosis will be enrolled. Participants will be asked to complete a single research visit, lasting approximately 2 hours, that will include the following procedures: - Participants will be asked to fast for 12 hours prior to arriving. - An IV will be placed and a blood sample collected (~11mL, if necessary). - Participants will undergo a research MRI lasting approximately 1.5 hours (up to 1 hour of total scan time) - All participants will be positioned in the MRI scanner for the initial scanning session (30 min) during which the first dose of GBCA (3/4 of total dose) or the total dose of Ferumoxytol will be administered. - The first 50 participants will be removed from the scanner bore, repositioned, and scanned for an additional 15 minutes (repeatability testing). - All participants will then be removed from the scanner and asked to consume 16 ounces of Ensure Plus®. After 20 minutes, they will be repositioned in the scanner for an additional scanning session (15 min) during which, a second dose of GBCA (1/4 of total dose) will be administered if required. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04867954
Study type Observational
Source University of Wisconsin, Madison
Contact Gemma Gliori, MS
Phone 608-262-7269
Email [email protected]
Status Not yet recruiting
Phase
Start date February 2022
Completion date April 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04604860 - Use of EL-FIT App to Promote Physical Activity N/A
Active, not recruiting NCT01438970 - Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function Phase 2
Recruiting NCT04581369 - Cirrhosis Medical Home N/A
Recruiting NCT04588077 - Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis Phase 4
Recruiting NCT04082780 - Rifamycin in Minimal Hepatic Encephalopathy Phase 2
Recruiting NCT03850977 - Is There an Association Between Chronic Pancreatitis and Pulmonary Function
Recruiting NCT03437876 - Study on Effect of Intestinal Microbiota Transplantation in Hepatitis B Virus Induced Cirrhosis N/A
Recruiting NCT04643795 - Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects Phase 1
Active, not recruiting NCT02344680 - Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Recruiting NCT04121520 - Perioperative Care of HVPG Measurement (CHESS1904): An International Multicenter Survey
Not yet recruiting NCT04591522 - Fecal Microbiota Transplantation in Cirrhosis N/A
Withdrawn NCT03309592 - Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension Phase 4
Active, not recruiting NCT03969186 - Telehealth Intervention in Cirrhotics N/A
Enrolling by invitation NCT04178096 - Using Data-Driven Implementation Strategies to Improve the Quality of Cirrhosis Care N/A
Recruiting NCT04221347 - Novel Molecular Spectrometric Biomarkers in Blood Plasma as an Early Diagnostic Tool in HCC
Recruiting NCT04195724 - Microbiome Translocation in Different Circulatory Compartments in Decompensated Cirrhosis N/A
Not yet recruiting NCT04592744 - Angiotensin 2 for AKI After OLT Phase 4
Recruiting NCT04322201 - Continuous Passive Paracentesis for Intra-abdominal Hypertension N/A
Completed NCT00244751 - Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects Phase 2
Recruiting NCT04460222 - Rotational Thromboelastometry Guided Blood Component Use in Children With Cirrhosis Undergoing Invasive Procedures: A Randomized Controlled Trial N/A